LENZ Therapeutics Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
LENZ Therapeutics Inc.
Ownership
Public
Status
Active
Headquarters country
United States
Ticker symbol
LENZ
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001815776

Board of directors

Follow this board

Chief executives

Joshua Lehrer-Graiwer · PRESIDENT AND CEO
Dates unknown
Evert B. Schimmelpennink · President, CEO and Secretary
Since March 2024

Board connections

14 of this board's directors also sit on 37 other boards.

Network of LENZ Therapeutics Inc.'s board connections Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Climb Bio Inc. Climb Bio Inc. Nkarta Inc. Nkarta Inc. Septerna Inc. Septerna Inc. Sionna Therapeutics Inc. Sionna Therapeutics In... SpyGlass Pharma Inc. SpyGlass Pharma Inc. ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Bicara Therapeutics Inc. Bicara Therapeutics In... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Century Therapeutics Inc. Century Therapeutics I... Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Jade Biosciences Inc. Jade Biosciences Inc. Abraham Bassan Abraham Bassan Joanne L. Viney Joanne L. Viney Joseph Jimenez Joseph Jimenez Kimberlee C. Drapkin Kimberlee C. Drapkin Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Rizzuto Carlo Rizzuto Carlo Zachary Scheiner Zachary Scheiner LENZ Therapeutics Inc.
Shared director Other board Same sector +21 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$654,873
6 purchases by 4 insiders
Sold, last 12 months
$10,613,117
8 sales by 2 insiders
Date Insider Transaction Shares Price Value
Mar 27, 2026 Jeffrey P. George Director Open-market purchase +5,592 $8.92 $49,881
Mar 27, 2026 Evert B. Schimmelpennink Director, Officer (President, CEO and Secretary) Open-market purchase +28,089 $8.95 $251,397
Mar 27, 2026 Chevallard Daniel R. Officer (Chief Financial Officer) Open-market purchase +7,500 $8.57 $64,275
Nov 17, 2025 Olsson Shawn Officer (Chief Commercial Officer) Option exercise +10,000 $2.08 $20,800
Nov 17, 2025 Olsson Shawn Officer (Chief Commercial Officer) Open-market sale −4,212 $25.74 $108,417
Nov 17, 2025 Olsson Shawn Officer (Chief Commercial Officer) Open-market sale −5,788 $26.37 $152,630
Nov 7, 2025 James W. Mccollum Director Open-market purchase +10,500 $22.79 $239,295
Nov 7, 2025 Chevallard Daniel R. Officer (Chief Financial Officer) Open-market purchase +20 $22.71 $454
Nov 7, 2025 Chevallard Daniel R. Officer (Chief Financial Officer) Open-market purchase +2,178 $22.76 $49,571
Sep 30, 2025 Versant Vantage II GP-GP, LLC 10% owner Open-market sale −49,701 $45.35 $2,253,940
Sep 30, 2025 Versant Vantage II GP-GP, LLC 10% owner Open-market sale −34,405 $45.35 $1,560,267
Sep 30, 2025 Versant Vantage II GP-GP, LLC 10% owner Open-market sale −83,066 $46.41 $3,855,093
Sep 30, 2025 Versant Vantage II GP-GP, LLC 10% owner Open-market sale −57,502 $46.41 $2,668,668
Sep 30, 2025 Versant Vantage II GP-GP, LLC 10% owner Open-market sale −177 $47.01 $8,321
Sep 30, 2025 Versant Vantage II GP-GP, LLC 10% owner Open-market sale −123 $47.01 $5,782

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.